OBJECTIVES: Purpose of this study was to evaluate quality of life (QoL) changes in MAP patients treated with orlistat according to the product licence. Orlistat, a clinically-effective, cost-effective treatment for weight reduction, is endorsed by NICE. MAP, the patient support programme, is endorsed by the UK Medicines Partnership project and provides direct support through trained health care professionals to patients treated with orlistat. METHODS: Patients starting treatment with orlistat and enrolled in the MAP programme were recruited into this study. Quality of life was measured using the 31-item, disease-specific IWQOL-Lite: Impact of Weight on Quality of Life questionnaire comprising five scales assessing physical function, self-esteem, sexual life, public distress, work and a total score. Weight, height and body mass index (BMI) were also collected at baseline, 3 and 6 months. Effect Size (ES) and Standardized Response Means (SRM) were used to assess clinically meaningful change for IWQOL-Lite subscales and total score, with values interpreted as small (0.20-0.50), moderate (0.51–0.80) and large (>=0.81). RESULTS: All patients (n=133) who achieved a weight reduction of at least 5% at 3 months as stipulated by the product licence were included in the analyses. Results of this study showed that these patients achieved clinically meaningful changes from baseline across all disease-specific QoL subscales, with moderate changes from baseline in physical function (ES=0.61; SRM=0.77), and moderate to large changes from baseline in self-esteem (ES=0.66; SRM=0.91) and IWQOL-Lite total score (ES=0.70; SRM=0.94). CONCLUSIONS: These findings clearly demonstrate that a weight reduction of at least 5% in patients taking orlistat enrolled in the MAP programme translates into clinically significant improvements across all disease-specific QoL domains. It can therefore be concluded that a combination of effective treatment with orlistat and direct patient support provided by health care professionals through the MAP programme results in clear benefits for these patients.